New trends in the treatment of bone metastasis
- 22 October 2007
- journal article
- review article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 102 (5) , 1095-1102
Abstract
Bone metastasis is often the penultimate harbinger of death for many cancer patients. Bone metastases are often associated with fractures and severe pain resulting in decreased quality of life. Accordingly, effective therapies to inhibit the development or progression of bone metastases will have important clinical benefits. To achieve this goal understanding the mechanisms through which bone metastases develop and progress may provide targets to inhibit the metastases. In the past few years, there have been advances in both understanding the mechanisms through which bone metastases develop and how they impact bone remodeling. Additionally, gains in promising clinical strategies to target bone metastases have been developed. In this prospectus, we will discuss some of these advances. J. Cell. Biochem. 102: 1095–1102, 2007.Keywords
This publication has 64 references indexed in Scilit:
- An Osteoprotegerin-like Peptidomimetic Inhibits Osteoclastic Bone Resorption and Osteolytic Bone Disease in MyelomaCancer Research, 2007
- The RANK/RANKL/OPG triad in cancer-induced bone diseasesCancer and Metastasis Reviews, 2006
- Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agentsPeptide Science, 2006
- Immunohistochemical analysis of low-grade and high-grade prostate carcinoma: relative changes of parathyroid hormone-related protein and its parathyroid hormone 1 receptor, osteoprotegerin and receptor activator of nuclear factor-kB ligandJournal of Clinical Pathology, 2006
- Expression of receptor activator of nuclear factor κβ ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variablesJournal of Clinical Pathology, 2006
- Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of boneBone, 2001
- Optimising treatment of bone metastases by Aredia™ and Zometa™Breast Cancer, 2000
- Interactions between Cancer and Bone Marrow Cells Induce Osteoclast Differentiation Factor Expression and Osteoclast-like Cell Formation in VitroBiochemical and Biophysical Research Communications, 2000
- Bisphosphonates as anticancer drugsExpert Opinion on Investigational Drugs, 1999
- The role of bisphosphonates in the treatment of bone metastases — the U.S. experienceSupportive Care in Cancer, 1996